NCT07609576Recruiting
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
Multicenter Study Proposal: Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
Source: ClinicalTrials.gov · Last updated 27 May 2026
Brief summary (registry, in English)
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies. Secondary objectives include identifying risk factors associated with infection, comparing infectious outcomes across different hematologic malignancies and BsAb types, and assessing the impact of infections on overall treatment outcomes.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 14 May 2026
- Start date
- 14 May 2026
- Primary completion date
- 15 Jun 2026
- Lead sponsor
- Infanta Leonor University Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT07609576
What you commit to
- Study type: Observational
- Planned participants: 350
- From 14 May 2026 to the primary completion date, 15 Jun 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Adult patients (≥18 years) diagnosed with hematologic malignancies (e.g., multiple myeloma, non-Hodgkin lymphoma) who are receiving treatment with bispecific antibodies.
- Patients must have initiated BsAb therapy within 30 days prior to study enrollment.
- Ability to provide informed consent.
- Severe infections will be recorded the first year, but infectious events past confirmed relapse or new treatments for the underlying disease will not be recorded.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Infanta Leonor University Hospital Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| University Hospital Infanta Leonor Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.